Effectiveness of eptinezumab 300 mg dose escalation in partial responders to 100 mg among patients with difficult-to-treat migraine: A prospective, real-world study by the GRASP study group.

Dermitzakis EV, Argyriou AA, Rikos D, Chondrogianni M, Foska A, Dimitriadou E, Tsironis C, Soldatos P, Tsolaki A, Giakoumakis E, Kaligianni ME, Litsardopoulos P, Vikelis M, Greek Research Alliance for the Study of headache and Pain (GRASP) study group

Open source

DOI: 10.1177/03331024261498883
Published: 2026 Oct
Container: Cephalalgia : an international journal of headache
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1177/03331024261498883,
  title = {Effectiveness of eptinezumab 300 mg dose escalation in partial responders to 100 mg among patients with difficult-to-treat migraine: A prospective, real-world study by the GRASP study group.},
  author = {Dermitzakis EV and Argyriou AA and Rikos D and Chondrogianni M and Foska A and Dimitriadou E and Tsironis C and Soldatos P and Tsolaki A and Giakoumakis E and Kaligianni ME and Litsardopoulos P and Vikelis M and Greek Research Alliance for the Study of headache and Pain (GRASP) study group},
  year = {2026},
  journal = {Cephalalgia : an international journal of headache},
  doi = {10.1177/03331024261498883},
  url = {https://doi.org/10.1177/03331024261498883}
}

RIS

TY  - JOUR
TI  - Effectiveness of eptinezumab 300 mg dose escalation in partial responders to 100 mg among patients with difficult-to-treat migraine: A prospective, real-world study by the GRASP study group.
AU  - Dermitzakis EV
AU  - Argyriou AA
AU  - Rikos D
AU  - Chondrogianni M
AU  - Foska A
AU  - Dimitriadou E
AU  - Tsironis C
AU  - Soldatos P
AU  - Tsolaki A
AU  - Giakoumakis E
AU  - Kaligianni ME
AU  - Litsardopoulos P
AU  - Vikelis M
AU  - Greek Research Alliance for the Study of headache and Pain (GRASP) study group
PY  - 2026
JO  - Cephalalgia : an international journal of headache
DO  - 10.1177/03331024261498883
UR  - https://doi.org/10.1177/03331024261498883
ER  -

APA

EV, D., AA, A., D, R., M, C., A, F., E, D., C, T., P, S., A, T., E, G., ME, K., P, L., M, V., & group, G. R. A. F. T. S. O. H. A. P. (. S. (2026). Effectiveness of eptinezumab 300 mg dose escalation in partial responders to 100 mg among patients with difficult-to-treat migraine: A prospective, real-world study by the GRASP study group.. Cephalalgia : an international journal of headache. https://doi.org/10.1177/03331024261498883

Source records

pubmed · retrieved 2026-11-10T14:01:26.880Z